Clinical Study
Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy
Figure 2
Graph showing changes in the number of antiglaucomatous medications applied from baseline to 12 months after treatment. At every follow-up visit, compared to baseline, the number of antiglaucomatous medications undertaken significantly reduced ().